#enoxaparin sodium injection

[sanjar2014]

Health risks in winter.

During the winter months, the risk of blood clotting, or thrombosis, tends to increase due to several factors. Cold temperatures cause blood vessels to constrict, which slows blood flow and heightens the likelihood of clot formation. Additionally, people are generally less active in colder weather, leading to prolonged periods of immobility that can result in blood pooling, particularly in the legs. Winter also brings a rise in respiratory infections, such as influenza and COVID-19, which can trigger systemic inflammation and further elevate clotting risks. Other contributing factors include dehydration from lower humidity levels caused by indoor heating, increased holiday travel involving long periods of sitting, and potential vitamin D deficiencies due to reduced sunlight exposure—all of which collectively enhance the propensity for blood clots during the colder season.

To prevent and treat blood clots, various medicines are employed, primarily falling into categories such as anticoagulants, antiplatelet agents, and thrombolytics. Anticoagulants like Warfarin and direct oral anticoagulants (e.g., Apixaban, Rivaroxaban) reduce the blood’s ability to form clots and are commonly used for long-term management. Antiplatelet agents, including Aspirin and Clopidogrel, prevent platelets from clumping together, thus reducing the risk of arterial clots. In emergency situations, thrombolytics such as Alteplase are used to dissolve existing clots. Additionally, non-medication approaches like compression stockings are recommended to enhance blood flow, especially during periods of immobility. Preventative strategies during winter also emphasize staying hydrated, maintaining regular physical activity, avoiding prolonged immobility, dressing warmly to prevent excessive vasoconstriction, and managing underlying health conditions. It is essential for individuals at higher risk of thrombosis to consult healthcare providers for personalized advice and appropriate treatment plans.

4o

[livealthbiopharma]

https://livealthbiopharma.com/products/enoxaparin-sodium-injection-usp-60-mg/

[gireportstory]

Global Bovine Heparin Sodium Market [2024-2030] | Market Size, Growth, Dynamics and Trends

Global Info Research’s  report offers key insights into the recent developments in the global Bovine Heparin Sodium market that would help strategic decisions. It also provides a complete analysis of the market size, share, and potential growth prospects. Additionally, an overview of recent major trends, technological advancements, and innovations within the market are also included.Our report further provides readers with comprehensive insights and actionable analysis on the market to help them make informed decisions. Furthermore, the research report includes qualitative and quantitative analysis of the market to facilitate a comprehensive market understanding.This Bovine Heparin Sodium research report will help market players to gain an edge over their competitors and expand their presence in the market.

According to our (Global Info Research) latest study, the global Bovine Heparin Sodium market size was valued at USD 41 million in 2023 and is forecast to a readjusted size of USD 60 million by 2030 with a CAGR of 5.6% during review period.

Bovine intestinal enoxaparin sodium and its injections can be used in anticoagulant, antithrombotic, anti-inflammatory, anticancer and halal drugs, that is, it has the halal property that porcine enoxaparin sodium does not have, and is widely used in Muslims, countries and countries. The region has a huge market. Global 5 largest manufacturers of Bovine Heparin Sodium are Bacto Chem, Syntex, Kin Master Produtos Químicos Ltda, Alliance Brasil and Ralington Pharma, which make up over 70%. Among them, Bacto Chem dominates with over 20% production value share, followed by Syntex (17%) and Kin Master Produtos Químicos Ltda (14%). Top manufacturers are based in South America, India and China.

Asia Pacific is the largest market, holding a share over 30%, followed by Europe and South America, with shares 30% and 20% separately.

Based on the product type, the Bovine Heparin Sodium is split into Type A and Type B.

Based on the product Application, the Bovine Heparin Sodium is primarily split into Treatment of Venous Thromboembolism, Cardioversion of Atrial Fibrillation/Flutter and Complications of Pregnancy. The largest segment is Treatment of Venous Thromboembolism, accounting for nearly 70%.

The Global Info Research report includes an overview of the development of the Bovine Heparin Sodium industry chain, the market status of Treatment of Venous Thromboembolism (Type A, Type B), Cardioversion of Atrial Fibrillation/Flutter (Type A, Type B), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Bovine Heparin Sodium.

Regionally, the report analyzes the Bovine Heparin Sodium markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Bovine Heparin Sodium market, with robust domestic demand, supportive policies, and a strong manufacturing base.

We have conducted an analysis of the following leading players/manufacturers in the Bovine Heparin Sodium industry: Kin Master Produtos Químicos Ltda、Syntex、Bacto Chem、Wegmed - Caminhos Medicinais Ltda、Alliance Brasil、Ralington Pharma、Hebei Changshan Biochemical Pharmaceutical、Suzhou Ronnsi Pharma Market segment by Type： Type A、Type B Market segment by Application：Treatment of Venous Thromboembolism、Cardioversion of Atrial Fibrillation/Flutter、Complications of Pregnancy、Others Report analysis: The Bovine Heparin Sodium report encompasses a diverse array of critical facets, comprising feasibility analysis, financial standing, merger and acquisition insights, detailed company profiles, and much more. It offers a comprehensive repository of data regarding marketing channels, raw material expenses, manufacturing facilities, and an exhaustive industry chain analysis. This treasure trove of information equips stakeholders with profound insights into the feasibility and fiscal sustainability of various facets within the market. Illuminates the strategic maneuvers executed by companies, elucidates their corporate profiles, and unravels the intricate dynamics of the industry value chain. In sum, the Bovine Heparin Sodium report delivers a comprehensive and holistic understanding of the markets multifaceted dynamics, empowering stakeholders with the knowledge they need to make informed decisions and navigate the market landscape effectively. Conducts a simultaneous analysis of production capacity, market value, product categories, and diverse applications within the Bovine Heparin Sodium market. It places a spotlight on prime regions while also performing a thorough examination of potential threats and opportunities, coupled with an all-encompassing SWOT analysis. This approach empowers stakeholders with insights into production capabilities, market worth, product diversity, and the markets application prospects. Assesses strengths, weaknesses, opportunities, and threats, offering stakeholders a comprehensive understanding of the Bovine Heparin Sodium markets landscape and the essential information needed to make well-informed decisions. Market Size Estimation & Method Of Prediction

Estimation of historical data based on secondary and primary data.

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Request Customization of Report@ https://www.globalinforesearch.com/contact-us About Us: Global Info Research is a company that digs deep into Global industry information to Bovine Heparin Sodium enterprises with market strategies and in-depth market development analysis reports. We provide market information consulting services in the Global region to Bovine Heparin Sodium enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.

[pawannbishnoiii]

Enoxaget: Blood Thinner Medication

Enoxaparin, marketed under the brand name Clexane, is an injectable medication that contains enoxaparin sodium as its active ingredient. It belongs to the class of drugs called low molecular weight heparins (LMWHs).

USES AND BENIFITS

Clexane injection (enoxaparin injection or enoxaparin sodium) has various uses and benefits. Here are some key points:

Prevention of blood clots: Enoxaparin is commonly used for the prevention of blood clots in both surgical and non-surgical patients. It helps reduce the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), which can be life-threatening conditions.

Treatment of blood clots: Enoxaparin is also used for the treatment of existing blood clots. It can help dissolve the clot and prevent further complications.

Management of unstable angina and heart attacks: In individuals with unstable angina or undergoing certain heart procedures, enoxaparin injection is often administered to prevent blood clots from forming or worsening.

SIDE EFFECTS

Some possible side effects of Enoxaparin (Clexane) injection, using the given keywords, include:

Bleeding: Enoxaparin is an anticoagulant medication and can increase the risk of bleeding. This can manifest as nosebleeds, easy bruising, prolonged bleeding from cuts, or blood in urine or stool.

Injection site reactions: Common side effects of Enoxaparin injection include pain, redness, or bruising at the injection site. Rarely, it can cause skin necrosis (death of skin tissue) at the injection site.

Allergic reactions: Some individuals may experience an allergic reaction to Enoxaparin injection, which can present as hives, rash, itching, difficulty breathing, swelling of the face or throat.

[emedicartstore]

enoxaparin 40 mg is an anticoagulant (blood thinner) used prevent blood clots

[akashpawar0412]

Enoxaparin Sodium Injection Market Value Report Forecast 2022-2030

Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country. 

Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology

Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/enoxaparin-sodium-injection-market

Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.

Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.

The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.

This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.

This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.

Market Segment Analysis:

Leading players of Enoxaparin Sodium Injection including:

Sanofi

Teva

Techdow (Hepalink)

Fresenius Kabi

Rovi

Amphastar

Nanjing King-friend

Sandoz

Apotex

Hangzhou Jiuyuan Gene Engineering

Cipla

Taj Pharma

Chengdu Baiyu Pharmaceutical

Suzhou Erye Pharmaceutical

Changzhou Qianhong Bio-pharma

Hebei Changshan Biochemical Pharmaceutical

Beijing SL Pharmaceutical

The information for each competitor/Company Profile includes:

Company Overview

Business Strategy

Key Product Offerings

Financial Performance

Key Performance Indicators

Risk Analysis

Recent Development

Regional Presence

SWOT Analysis

Market split by Type, can be divided into:

30 mg/0.3mL

40 mg/0.4mL

60 mg/0.6mL

80 mg/0.8mL

100 mg/1mL

Market split by Application, can be divided into:

Hospital

Clinic

Others

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.

Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.

The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.

Market segment by Region/Country including:

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others

• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region. 

• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.

• To profile key players and comprehensively analyze their market position in terms of core competencies.

• To analyze the markets situation with regard to industry trends, prospects, and contribution  to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Key Reasons to Purchase:

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/enoxaparin-sodium-injection-market

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: help@intelmarketresearch.com Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research

[stanexdnc]

Buy Stapinox 40 Mg Online

Stapinox is a drug that is mainly composed of Enoxaparin which inhibits blood clots in patients. It is used to treat patients with complications in blood vessels caused due to heart attacks. It is also used in patients suffering from angina. It works by preventing blood clot formation and also prevents blockages in the blood vessels of the body. Depending on the condition of the patient and the ailment, various doses of this drug is available to the patients such as 20mg, 40mg, 80mg PFS.  While the drug is completely safe for use, it’s always a good practice to check for any allergic reaction the patient might have especially if they have a history of allergic reaction to drugs. Doctors can administer a small/standard dose of the drug to check how the patient reacts to it before considering a more potent dose.

At Stanex, we invest our time and effort not only in improving the existing portfolio of life-saving drugs in our inventory but also employ innovative R&D methodology to find new drugs that can save lives and improve everyone’s well-being all around. As a WHO-GMP and USFDA recognised company, our products undergo a series of quality checks to ensure it meets the expected quality norms without fail at all time. Additionally, we also manufacture our products as per the global specifications with IP/BP/USP specifications. As a company that has footprints in over 50 countries globally, it becomes imperative for us not only to meet supply and demand but also ensure every single unit of drug that leaves our premises is safe and effective for its intended purpose. To know more, visit our website now.

[sriyalifescience]

What prevents deep venous thrombosis?

What is Enoxaparin?

Enoxaparin Sodium Injection (Elaxan) is an anticoagulant that prevents blood clots from forming.

Deep vein thrombosis (DVT) is a form of blood clot that can develop into blood clots in the lungs. Enoxaparin is utilized to treat or forestall DVT (pneumonic embolism). DVTs can create after specific kinds of a medical procedures or in people who have been incapacitated for quite a while because of affliction.

In people with specific types of angina (chest uneasiness) or cardiovascular failure, enoxaparin is additionally used to stay away from vein issues.

Sriya Life Science is a certified Enoxaparin Manufacturer. It has expanded its business throughout all the parts of the world thereby providing service across the globe.

What is it used for?

Enoxaparin is a medication that is used to prevent deep venous thrombosis, a disease in which dangerous blood clots develop in the legs' blood arteries. These blood clots can make their way to the lungs and become stuck in the lungs' blood arteries, resulting in pulmonary embolism. When you are unable to walk for many days after hip or knee replacement surgery, or in rare circumstances after abdominal surgery, this drug is administered. Blood clots are more prone to develop during this period. If you are unable to get out of bed due to a major sickness, enoxaparin may be taken.

Furthermore, during certain forms of chest discomfort and heart attacks, enoxaparin is induced to prevent blood clots from developing in the arteries of the heart.

To treat acute deep vein thrombosis with or without pulmonary embolism, enoxaparin is used with warfarin. It's also used to treat some sorts of heart attacks that aren't life-threatening.

This medication can only be obtained with a doctor's prescription.

How is the medicine taken?

Enoxaparin is a drug that is injected directly into the skin. Pinch the skin of your stomach between your finger and thumb to produce a fold and fix the pharmaceutical dose. After cleaning the region, hold the syringe in your hand like a pencil and push the needle into the skin fold. As directed by your prescribing physician, inject the drug and discard the syringe. Follow the healthcare provider's directions to the letter.

If you have any questions or experience any side effects from the drug, see your doctor.

Special care is taken by the Enoxaparin Manufacturerwhile making the product and covers all the necessary information that you should follow while taking this injection.

On what conditions should you not consume Enoxaparin?

On the off chance that you have a hypersensitivity to enoxaparin, heparin, benzyl liquor, or pork items, or then again assuming you have dynamic or uncontrolled dying, or on the other hand assuming you have had diminished platelets in your blood in the last 100 days, you should not take it.

Enoxaparin may make you bleed more readily, especially if you have a bleeding issue that is either hereditary or caused by illness; a hemorrhagic stroke; a bacterial endocarditis infection; stomach or on the other hand gastrointestinal draining or ulcer; or late cerebrum, spine, or eye a medical procedure.

What are the side effects of Enoxaparin?

Coming up next are probably the most widely recognized adverse side effects:

· nausea

· vomiting

· diarrhea

· anaemia

· perplexity

Where the medicine is injected, there may be pain, bruising, redness, or irritation.

Sriya Life Science is a Certified Enoxaparin Manufacturer, who provides service all over the world and to every people in need. For any further assistance, contact them to know more.

[pharmatimesng]

Apotex Corp Recalls Enoxaparin Sodium Injection USP due to Mislabelling of Syringe Barrel Measurement Markings

Apotex Corp Recalls Enoxaparin Sodium Injection USP due to Mislabelling of Syringe Barrel Measurement Markings

  The National Agency for Food and Drug Administration and Control (NAFDAC) has received information from the US FDA that Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL…

[siglerprescriptiondrugcards]

Enoxaparin Sodium

Common Brand Names: Lovenox

Therapeutic Class: A low-molecular weight heparin

Common Injectable Dosage Forms:

Solution for Injection (prefilled syringes): 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL, 90 mg/0.6 mL, 120 mg/0.8 mL, 150 mg/mL

Solution for Injection (multi-dose vials): 100 mg/mL (3 mL vials)

Dosage Ranges:

For the prophylaxis of deep vein thrombosis (DVT) after hip or knee replacement: 30 mg every 12 hours beginning 12-24 hours after operation and continue for 7-10 days. May be use 40 mg once daily for 3 weeks post operation.

For the prophylaxis of DVT after abdominal surgery: 40 mg/day beginning 2 hours prior to surgery and continue for 7-10 days post operation.

For treatment of DVT with or without pulmonary embolism (PE): 1 mg/kg every 12 hours or 1.5 mg/kg/day.

Administration and Stability: Administer by subcutaneous route only. Do not administer intramuscularly. To avoid loss of drug, do not expel air bubble prior to injection. Administer by deep SC injection alternating between left and right anterolateral and left and right posterolateral abdominal wall. Store at controlled room temperature. pH 5.5-7.5

Pharmacology/Pharmacokinetics: Enoxaparin sodium is a low-molecular weight heparin which has antithrombotic properties. In humans, enoxaparin has a higher ratio of anti-Factor Xa to anti-Factor IIa activity compared to heparin. Maximum anti-Factor Xa and antithrombin (anti-Factor IIa) activities occur 3-5 hours after SC injection. Elimination half-life based on anti-Factor Xa activity is 4.5 hours after SC injection. Anti-Factor Xa activity persists for about 12 hours.

Drug and Lab Interactions: Drugs which affect platelet function (ASPIRIN, NSAIDs, DIPYRIDAMOLE, TICLOPIDINE) may increase risk of hemorrhage and should be used with caution. Concomitant use of STREPTOKINASE and UROKINASE may result in hemorrhage and should be avoided. Enoxaparin prolongs prothrombin time and care should be used in evaluating this test in patients in warfarin or other anticoagulants which use this test as a therapeutic monitor. Do not mix with other injections. May cause asymptomatic reversible increases in aspartate (AST) and alanine (ALT) aminotransferase levels.

Contraindications/Precautions: Contraindicated in patients hypersensitive to heparin, pork products, benzyl alcohol, or sulfites, and in patients with a history of heparin-induced thrombocytopenia or active major bleeding. Cases of epidural or spinal hematomas have been reported with the associated use of enoxaparin and spinal/epidural anesthesia or spinal puncture resulting in long-term or permanent paralysis. Pregnancy Category B.

Monitoring Parameters: Platelets, occult blood, anti-Xa activity, PT if applicable

Adverse Effects: The most common adverse reaction of parenteral administration is local reaction at the site of injection. May also cause hemorrhage, edema, and anemia.

Common Clinical Applications: An effective parenteral anticoagulant used in therapy or prophylaxis of thrombosis or thromboembolism following surgery or complications from unstable angina and myocardial infarction.

[joinhubpharma]

JoinHub Pharma is a WHOGMP pharmaceutical company approved for Enoxaparin Sodium Injection manufacturer in India

https://joinhubpharma.com/covid-medicines/

[meulcerativecolitisandibd]

Medications past and present

Medications Past:  

Cyclosporine (immunosuppressive organ transplant meds taken for colitis) - intravenous and oral Azathioprine (immunosuppressive chemo meds taken for colitis) - oral (never successful) Prednisolone (immunosuppressive steroids taken for colitis) - intravenous and oral (never successful) Methotrexate (immunosuppressive chemo meds taken for colitis) - oral Alendronic acid (bone density meds taken for bone problems) - oral Adalimumab (immunosuppressive colitis meds taken for colitis) - injection (self administered) Enoxaparin sodium (anticoagulant) - injection (self administered following surgery) Mesalazine enemas (colitis meds taken for colitis) - enema (only taken during severe flare up - never successful) Prednisolone suppository (immunosuppressive colitis meds taken for colitis) - suppository (only taken during severe flare up - never successful) Metranidozole (antibiotic taken for infection following surgery and following dental work) - intravenous and oral Cefradine (antibiotic taken for infection following surgery)  - intravenous and oral Amoxycillin (antibiotic taken for various infections) - oral Influenza vaccination (flu vaccination) - annual injection Pneumonia vaccination (pneumonia vaccination) - five yearly injection

Medications Present: 

Vedulizumab (immunosuppressive colitis meds taken for colitis) - intravenous B12 (anemia meds taken for pernicious anemia) - injection Mesalazine (colitis meds taken for colitis) - oral Valaciclovir (herpes simplex meds taken for herpes simplex) - oral Lanzoprazole (proton pump inhibitor meds taken for hernia and acid reflux) - oral Calcium and Vitamin D (bone density meds taken for bone problems) - oral Paracetamol (analgesic painkiller meds) - oral Prednisolone enemas (immunosuppressive colitis meds taken for colitis) - enema (only taken during severe flare up - never successful)

Intravenous meds administered in hospital every eight weeks B12 injection administered and blood tests taken at doctor's surgery every twelve weeks All oral meds daily - total of 20 tablets a day

[stanexdrugs]

[akashpawar0412]

** Enoxaparin Sodium Injection Market Size Report Forecast 2022-2030**

Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country. 

Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology

Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/Enoxaparin-Sodium-Injection-Market

Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.

Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.

The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.

This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.

This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.

Market Segment Analysis:

Leading players of Enoxaparin Sodium Injection including:

Sanofi

Teva

Techdow (Hepalink)

Fresenius Kabi

Rovi

Amphastar

Nanjing King-friend

Sandoz

Apotex

Hangzhou Jiuyuan Gene Engineering

Cipla

Taj Pharma

Chengdu Baiyu Pharmaceutical

Suzhou Erye Pharmaceutical

Changzhou Qianhong Bio-pharma

Hebei Changshan Biochemical Pharmaceutical

Beijing SL Pharmaceutical

The information for each competitor/Company Profile includes:

Company Overview

Business Strategy

Key Product Offerings

Financial Performance

Key Performance Indicators

Risk Analysis

Recent Development

Regional Presence

SWOT Analysis

Market split by Type, can be divided into:

30 mg/0.3mL

40 mg/0.4mL

60 mg/0.6mL

80 mg/0.8mL

100 mg/1mL

Market split by Application, can be divided into:

Hospital

Clinic

Others

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.

Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.

The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.

Market segment by Region/Country including:

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others

• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region. 

• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.

• To profile key players and comprehensively analyze their market position in terms of core competencies.

• To analyze the markets situation with regard to industry trends, prospects, and contribution  to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Key Reasons to Purchase:

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/Enoxaparin-Sodium-Injection-Market

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: help@intelmarketresearch.com Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research/